Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible... Show more
TRDA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 16, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on June 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TRDA as a result. In of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TRDA entered a downward trend on June 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for TRDA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
TRDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.639) is normal, around the industry mean (17.006). P/E Ratio (12.121) is within average values for comparable stocks, (59.274). TRDA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.273). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.656) is also within normal values, averaging (256.503).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FESCX | 9.93 | 0.02 | +0.20% |
First Eagle Small Cap Opportunity I | |||
EGOIX | 18.36 | 0.03 | +0.16% |
Allspring Large Cap Core Inst | |||
HSMSX | 12.21 | 0.02 | +0.16% |
Hartford Small Cap Value R4 | |||
FAPLX | 12.52 | N/A | N/A |
Fidelity Advisor Healthy Future M | |||
PRJDX | 44.84 | -0.11 | -0.24% |
PGIM Jennison Global Opportunities R4 |
A.I.dvisor indicates that over the last year, TRDA has been loosely correlated with CRNX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if TRDA jumps, then CRNX could also see price increases.
Ticker / NAME | Correlation To TRDA | 1D Price Change % | ||
---|---|---|---|---|
TRDA | 100% | -5.13% | ||
CRNX - TRDA | 57% Loosely correlated | -1.13% | ||
ARCT - TRDA | 53% Loosely correlated | +0.57% | ||
BEAM - TRDA | 52% Loosely correlated | +1.92% | ||
VYGR - TRDA | 52% Loosely correlated | -2.56% | ||
XERS - TRDA | 51% Loosely correlated | +4.09% | ||
More |